This makes me incrementally more nervous for OGXI, as clearly not getting the axe before the R&D day doesn't mean you are home free...
True. The bottom line is that Teva is a very different company now than it was a few years ago. (The prospect of the end of Copaxone exclusivity in less than two years made the status quo an unappealing option.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.